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Protein Folding Activity of the 
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Stéphane Chédin3, Reynald Gillet4, Marie-Astrid Contesse1, Gaëlle Friocourt1, 
Guillaume Stahl5, Gary W. Jones2,# & Cécile Voisset1
6AP and GA are potent inhibitors of yeast and mammalian prions and also specific inhibitors of PFAR, 
the protein-folding activity borne by domain V of the large rRNA of the large subunit of the ribosome. 
We therefore explored the link between PFAR and yeast prion [PSI+] using both PFAR-enriched 
mutants and site-directed methylation. We demonstrate that PFAR is involved in propagation and de 
novo formation of [PSI+]. PFAR and the yeast heat-shock protein Hsp104 partially compensate each 
other for [PSI+] propagation. Our data also provide insight into new functions for the ribosome in basal 
thermotolerance and heat-shocked protein refolding. PFAR is thus an evolutionarily conserved cell 
component implicated in the prion life cycle, and we propose that it could be a potential therapeutic 
target for human protein misfolding diseases.
The infectious proteins concept was first established for the prion protein PrP in mammals with transmissible 
spongiform encephalopathy. In its PrPSc prion conformation, PrP accumulates as self-propagating amyloid fibers 
without prion-specific nucleic acid. Proteins behaving like prions have also been identified in the budding yeast S. 
cerevisiae, although it has no PrP homolog. The best studied yeast prions are [PSI+] and [URE3]: heritable amy-
loids of translation release factor Sup35p and nitrogen catabolism Ure2p regulator, respectively1,2.
Hsp104p is a cell factor known to be essential to prion propagation in yeast, in collaboration with heat-shock 
protein chaperones such as Hsp70p and Hsp40p, characterized as prion propagation modulators3. Hsp104p is a 
hexameric, ring-shaped ATPase of the AAA+ family with disaggregase, unfoldase and translocase activities4. In 
yeast, it has a prime role in disassembling and remodeling the aggregated proteome in collaboration with Hsp70 
and Hsp40, thereby providing thermotolerance5. Hsp104p also exhibits operational plasticity adaptable to the 
needs of the yeast proteome, including severing prion fibers by threading Sup35p through its hexameric pore6. 
In the current model, it thus acts as a “molecular sonicator” to transform highly aggregated dead-end fibers into 
low-molecular-weight oligomers that can seed new rounds of polymerization and enable efficient transmission 
from mother to daughter cells1,7. Thus, when Hsp104p is inhibited (e.g., by guanidine hydrochloride GdnHCl) or 
when HSP104 is deleted, cells are cured of [PSI+] prion, as fibers form and grow but are not severed to make new 
seeds. Hence, the number of fibers and seeds per cell decreases as cells divide, leading to prion-free cells1. In addi-
tion, Hsp104p overexpression cures [PSI+] prion, likely by complete prion fiber disaggregation to a soluble form; 
but the mechanism remains to be fully deciphered7–9. Metazoans lack Hsp104p orthologs; none of their AAA+ 
protein superfamily ATPases displays amyloid disaggregation comparable to Hsp104p5.
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In certain lab strains, [PSI+] prion-containing cells are easily differentiated from [psi−] counterparts by color. 
In [psi−] cells, Sup35p is soluble and causes the ribosome to stop translation at stop codons, including the pre-
mature stop codon in the ADE1 gene ade1-14 allele, leading to truncated non-functional Ade1 protein. Without 
Ade1p, colonies become red on YPD-rich medium as cells accumulate an intermediate metabolite of the adenine 
biosynthesis pathway1. When most Sup35p is sequestrated as amyloid, it fails in its role of translation termination, 
and the ribosome has an increased the tendancy to read through stop codons, including ade1-14 premature stop 
codon. Consequently, ade1-14 [PSI+] cells produce functional Ade1p enzyme and form white or pink colonies on 
YPD-rich medium. This white/red colorimetry was used for an antiprion drug-screening assay10. Using successive 
screenings for drugs able to cure the unrelated [PSI+] and [URE3] yeast prions as well as PrPSc mammalian prion, 
we showed some mechanisms controlling prion propagation to be conserved from yeast to humans10,11. These 
screenings identified several new antiprion compounds: 6-aminophenanthridine (6AP), guanabenz (GA, already 
used in hypertension) and imiquimod (IQ, a TLR7 agonist), all active against yeast and mammalian prions in 
vitro and in vivo10,12,13. 6AP and GA were independently shown to interact with specific domain V nucleotides of 
the large rRNA of the large 60S ribosome subunit14. Domain V of the large rRNA (23S in E. coli, 25S in S. cere-
visiae, 28S in metazoa) has 2 enzymatic activities, i) a peptidyl transferase activity and ii) a poorly characterized 
protein folding activity, PFAR: Protein Folding Activity of the Ribosome (in ref. 15; for reviews see16–18). PFAR 
was characterized by in vitro refolding experiments, showing that domain V of the large rRNA from bacteria, 
yeast or Drosophila assist protein folding of various denatured protein substrates14,17,19. PFAR was mainly studied 
in vitro and its biological role remains unclear. 6AP and GA are the first specific competitive inhibitors of PFAR 
not affecting ribosome peptidyl transferase activity11,20.
6AP, GA and IQ antiprion compounds display anti-PFAR activity, suggesting that PFAR may play an impor-
tant role in prion generation and propagation. Investigating links between PFAR and yeast prion [PSI+], we found 
PFAR to be involved in the propagation and de novo formation of [PSI+] in vivo. As these properties are remi-
niscent of Hsp104p, we explored the interplay between PFAR and Hsp104p and showed that PFAR and Hsp104p 
partially compensate each other for [PSI+] propagation. This is clear evidence of PFAR’s important role with 
fundamental implications for protein folding and perhaps for human protein misfolding diseases.
Results
[PSI+] propagation and de novo appearance are affected in PFAR-enriched cells. To determine 
whether PFAR is linked with prionization mechanisms in vivo in yeast, we first investigated the effect of PFAR 
enrichment on [PSI+] propagation. Several studies have shown that the protein folding activity of the ribosome 
is silenced when translation occurs15,17,21 and Mondal et al. recently demonstrated that a tRNA positioned at the 
P-site inhibits the ribosome’s chaperoning function22. We thus created yeast mutants enriched in free 60S subunits. 
The rational of our approach is that 60S free subunits are more prone to fulfill protein folding function than 
actively translating 80S ribosomes because they are not engaged in translation23. The folding process has indeed 
been shown to start with the full-length polypeptide chain splitting a non-translating ribosome into subunits23. 
Domain V nucleotides of the large rRNA that harbor PFAR are thereby easily accessible at the surface of the 60S 
subunit16,18. The large 60S subunit of the ribosome is actually able to fold proteins more efficiently than the whole 
ribosome in vitro, the small 40S subunit attenuating PFAR by partly masking domain V nucleotides that harbor 
PFAR21,23,24. This post-translational protein folding event is actually assumed to be a cooperative process to permit 
ribosome recycling17. We thus created 60S-enriched yeast mutants by deleting LTV1 and YAR1 genes in a [PSI+] 
strain: Ltv1p is involved in small 40S subunit transport from nucleus to cytoplasm, while Yar1p prevents aggrega-
tion of Rps3, a protein essential for 40S subunit maturation prior to translocation from nucleus to cytoplasm25–27. 
Compared to WT strain, ltv1Δ and yar1Δ mutant strains actually showed high rates of free 60S subunits and 
relative impoverishment in 40S subunits (Figs 1A and S1A).
To prove functional PFAR enrichment, we assessed whether enrichment in 60S increased protein-folding 
capacity in ltv1Δ and yar1Δ strains and first explored basal thermotolerance (non-induced thermotolerance). 
WT, ltv1Δ and yar1Δ [psi− ] strains were subjected to high temperature and surviving cells were scored at vari-
ous times in both HSP104 and hsp104Δ backgrounds. ltv1Δ and yar1Δ mutants proved more thermoresistant 
than WT strain (Fig. 1B), and also when combined with hsp104Δ versus hsp104Δ alone (Fig. 1C). Thus, PFAR 
enrichment conferred basal Hsp104-independent thermoresistance to ltv1Δ and yar1Δ strains. We next evalu-
ated the folding capacity of ltv1Δ and yar1Δ mutant strains by monitoring in vivo luciferase refolding following 
denaturation by heat shock: it proved more efficient in ltv1Δ and yar1Δ mutants than in WT strain (Fig. 1D) 
without affecting cell survival (Figure S1B). Remarkably, ltv1Δ and yar1Δ mutants combined with hsp104Δ 
showed better luciferase refolding than hsp104Δ alone (Fig. 1D) together with a better survival rate (Figure S1B), 
which is consistent with data shown in Fig. 1B,C. This enhanced folding capacity was abolished in presence of 
6AP (Fig. 1E): i.e., PFAR clearly influences the cellular response to heat shock, and is thus a protein chaperone 
genuinely involved in cellular refolding. Thus ltv1Δ and yar1Δ mutants displayed patently enhanced PFAR activ-
ity and are thus well suited to investigate PFAR involvement in [PSI+] prion propagation.
PFAR-enriched strains were then used to determine the effect of PFAR enrichment on [PSI+] propagation. As 
PFAR is the cellular target of the two antiprion drugs 6AP and GA, we first evaluated their ability to cure [PSI+] 
on PFAR-enriched strains ltv1Δ and yar1Δ . [PSI+] cells form white colonies whereas [psi− ] cells form red colo-
nies. GdnHCl was added to the medium to partially inhibit Hsp104p and thus favor the activity of drugs acting on 
conserved prion-controlling pathways distinct from Hsp104p10. The appearance of a halo of red colonies around 
a filter identifies a compound potentially active against [PSI+] prion28. Red halos around filters spotted with 6AP 
and GA were much smaller for ltv1Δ and yar1Δ mutants than WT strain (Fig. 2A) that indicates less efficient 
[PSI+] curing (Figure S2A). The mutants had read-through levels (Figure S2B), membrane permeability (Figure 
S2C) and contained a prion strain similar to that of WT strain (Figure S2D), suggesting that 6AP and GA were 
actually titrated out by the excess of their PFAR target. We next investigated the impact of PFAR enrichment on 
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[PSI+] propagation as the proportion of [psi− ] red colonies from [PSI+] colonies during cell division. As shown 
in Fig. 2B, the proportion of [psi− ] red colonies (YPD) was higher for ltv1Δ and yar1Δ mutants than WT strain: 
i.e., [PSI+] propagation was impaired in PFAR-enriched cells. Furthermore, the PFAR inhibitor 6AP restored 
[PSI+] stability in ltv1Δ and yar1Δ strains (Fig. 2B), which shows that PFAR enrichment itself, but not subunits 
imbalance, is responsible for impaired [PSI+] propagation. 6AP effect was reversible in cells grown on 6AP-free 
YPD medium (Fig. 2B, back to YPD) compared to 6AP-containing medium (Fig. 2B, back to 6AP). To confirm 
these data, we used Bms1p, a ribosome assembly GTPase involved in 40S subunit biogenesis, overexpression of 
which disturbs the 60S:40S ratio in favor of 60S subunits29 (Figure S2E). Like in ltv1Δ and yar1Δ strains, Bms1p 
overexpression in a WT [PSI+] strain made [PSI+] less susceptible to 6AP and GA antiprion drugs (Figure S2F) 
and reduced its propagation rate, as shown by the higher proportion of red [psi− ] colonies compared to WT strain 
(Fig. 2C). This agrees with the finding that Bms1p overexpression increased the rate of natively folded proteins 
heterologously overexpressed in yeast29.
In order to check that [PSI+] instability was a direct consequence of PFAR enrichment, we first analyzed 
[PSI+] propagation in rpl8a∆ cells which contain an increased amount of free 40S subunits30 and have a reduced 
growth rate similar to that of ltv1∆ and yar1∆ strains: [PSI+] stability was not altered in rpl8a∆ cells (Fig. 2D). 
Moreover, reducing free cytoplasmic rate of both 40S and 60S subunits by deleting LTV1 or YAR1 together with 
Figure 1. ltv1Δ and yar1Δ strains display PFAR enrichment. (A) Polysome profiles of WT, ltv1Δ and yar1Δ 
strains showing that ltv1Δ and yar1Δ mutant strains display elevated levels of free 60S subunits, as well as an 
impoverishment in 40S subunits compared to WT strain. 60S:40S ratios were 2.28 for the WT strain, 4.03 and 5.09 
for ltv1Δ and yar1Δ strains, respectively. The y axis shows arbitrary units. (B,C) Basal thermotolerance of PFAR-
enriched strains. WT, ltv1Δ and yar1Δ [psi− ] cells (B) or hsp104Δ , ltv1Δ /hsp104Δ and yar1Δ /hsp104Δ [psi− ]  
cells (C) were heat-shocked at 47 °C and aliquots harvested at specified incubation times and spread on YPD 
medium. Survival is the percentage of cells alive after heat shock compared to cells without heat shock. (D) Protein 
refolding in PFAR-enriched strains. WT, ltv1Δ , yar1Δ , hsp104Δ , ltv1Δ /hsp104Δ and yar1Δ /hsp104Δ [psi− ] 
cells were heat-shocked at 45 °C for 60 min. Protein synthesis was inhibited by cycloheximide and aliquots were 
harvested after specified post-heat-shock incubation periods, and luciferase activity was measured. (E) hsp104Δ , 
ltv1Δ /hsp104Δ and yar1Δ /hsp104Δ [psi− ] cells were pretreated by 200 μ M 6AP for 2 hrs and heat-shocked at 45 °C 
in continuous presence of 6AP for 1 hr as described above. Experiment were repeated 3 times. A representative assay 
including 3 technical repeats is shown with error bars. Bar height in panels (B–D) represents the mean; *P < 0.05 or 
**P < 0.001 on t-test, relative to WT strain (panels B,D), hsp104Δ strain (panels C,D) or 6AP-treated cells (panel E).
www.nature.com/scientificreports/
4Scientific RepoRts | 6:32117 | DOI: 10.1038/srep32117
Figure 2. PFAR involvement in [PSI+] propagation and de novo appearance. (A) WT, ltv1Δ and yar1Δ 
[PSI+] strains were spread on GdnHCl-supplemented medium (200 μ M). DMSO (compound vehicle) and 
GdnHCl (3 μ moles) were applied to top left and bottom right filters, respectively (see Supporting experimental 
procedures for further details). Bottom panels: ltv1Δ and yar1Δ colony phenotypes. (B) [PSI+] stability was 
evaluated by scoring [psi− ] colonies appearing from [PSI+] cells as percentage of total cells for WT and ltv1Δ 
and yar1Δ strains. The effect of 6AP on [PSI+] stability was evaluated by scoring [psi− ] red colonies from  
[PSI+] cells plated on medium supplemented with 50 μ M 6AP. 6AP treatment reversibility was analyzed by 
spreading [PSI+] cells from 6AP-containing plates on YPD plates (back to YPD) or on 6AP-containing plates 
(50 μ M) as control (back to 6AP). (C) [PSI+] WT weak strain was transformed either by a plasmid expressing 
BMS1 under a galactose-induced promoter or by empty vector. [PSI+] stability was evaluated by scoring [psi− ] 
colonies from [PSI+] cells on a medium containing glucose (gray bars) or galactose (black bars). (D) [PSI+] 
stability was evaluated by scoring [psi− ] colonies appearing from [PSI+] cells as percentage of total cells for WT, 
rpl8aΔ , ltv1Δ , rpl8aΔ /ltv1Δ , yar1Δ and rpl8aΔ /yar1Δ strains. (E) Protein expression profiles of ltv1Δ and 
yar1Δ mutants were analyzed by 2D-gel electrophoresis. (F) Hsp104p and Sup35p expression was analyzed by 
SDS-PAGE. Actin was used as a loading control. (G) [PSI+] WT, ltv1Δ , yar1Δ and erg6Δ cells were streaked on 
plates containing 0 or 5 mM GdnHCl. (H) De novo [PSI+] colony formation from ltv1Δ and yar1Δ [psi− ] cells 
was monitored on adenine-free medium where only [PSI+] cells could grow. [PSI+] status of white and pink 
colonies growing on adenine-free medium was confirmed by curing with GdnHCl. Averages of 4 experiments 
including 5 technical repeats are shown with error bars. Bar height of panels (B,C,H) represents the mean; 
*P < 0.05 or **P < 0.001 on t-test versus WT cells grown on YPD (panel B), cells transformed with empty 
plasmid and grown on galactose-containing medium (panel C), or WT strain (panel H).
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RPL8A did not affect [PSI+] stability despite the reduced growth rate of the double mutants ltv1∆ /rpl8a∆ and 
yar1∆ /rpl8a (Fig. 2D). These data showed that neither the decreased growth rate of ltv1∆ and yar1∆ cells nor 
the perturbation of subunit ratio is responsible for [PSI+] instability. We next analyzed ltv1Δ and yar1Δ mutants 
protein expression profiles: they were similar to that of WT strain (Fig. 2E), suggesting that global protein syn-
thesis, in particular Hsp104p level (Fig. 2F), was not impaired in PFAR-enriched cells. Finally, as modification 
of Hsp70 expression level also leads to [PSI+] instability31, we checked that GdnHCl sensitivity was similar in 
WT and ltv1Δ and yar1Δ cells (Fig. 2G), indicating that Hsp70 function is not deficient in PFAR-enriched 
cells. Only erg6Δ cells (previously described as hypersensitive to guanidine toxicity31) were not able to grow 
in presence of 5 mM GdnHCl. Taken together, these data suggest that PFAR is a cellular modulator of [PSI+] 
propagation.
The study revealed a peculiar finding concerning the yeast [URE3] prion: PFAR enrichment in yar1Δ [URE3] 
strain (NT64 strain) dramatically increased [URE3] stability (Figure S2G), whereas [PSI+] stability was reduced 
in PFAR-enriched ltv1Δ and yar1Δ strains (Fig. 2B). For unknown reasons this “WT” yeast strain has a low level 
of 60S subunits compared to the 74-D694 strain background (Figure S2H). Thus the deletion of YAR1, instead of 
massively enriching cells in 60S free subunits, only restored a PFAR level better sustaining [URE3] propagation. 
Thus, propagation of [URE3], like [PSI+], relies on PFAR. However, PFAR enrichment of the NT64 [URE3] strain 
only restored a PFAR level maintaining [URE3] propagation.
We next investigated whether PFAR is also involved in spontaneous generation of [PSI+] and observed that 
its rate was slightly but significantly higher in ltv1Δ and yar1Δ strains than WT (Fig. 2H). We concluded that 
enhancing PFAR potentiates Sup35p conversion to the prion state, suggesting that PFAR helps Sup35p reach a 
prion-inducing conformation. Together with the impact of PFAR enrichment on [PSI+] propagation, this high-
lighted the role of PFAR in prionization.
Alteration of PFAR rRNA nucleotides impairs [PSI+] propagation. We next investigated the effect of 
PFAR inhibition on [PSI+] propagation by altering PFAR rRNA nucleotides using site-directed methylation32,33. 
Site-directed methylation is based on the hijacking of naturally encoded small nucleolar RNAs (snoRNA) to 
specifically methylate nucleotides at rRNA level and can be achieved by replacing the cellular snoRNA guide 
element by a custom guide sequence32. The nucleotide to be modified is targeted through specific base pair-
ing of the snoRNA guide sequence with its rRNA substrate (Fig. 3A). Adding an unnatural methyl moiety to 
a rRNA specific nucleotide using the cellular machinery is equivalent to a gene-product point mutation33. We 
focused on U2862 and G2863 nucleotides which are collectively conserved in bacterial, yeast and human domain 
V (Fig. 3B), involved in ribosome protein folding in vitro14, able to bind 6AP and GA14 and not naturally methyl-
ated34. We thus generated PFAR-snoRNAs specifically targeting these two nucleotides of domain V of yeast 25S 
rRNA and expressed them in WT [PSI+] cells. [PSI+] stability was assessed as the proportion of [psi− ] red col-
onies spontaneously appearing from WT [PSI+] white colonies expressing these PFAR-snoRNAs. Expression of 
PFAR-snoRNA targeting nucleotide U2862 led to a larger proportion of [psi− ] red cells than cells transformed by 
PFAR-snoRNA targeting nucleotide G2863 and negative controls (Fig. 3C), suggesting nucleotide U2862 methyl-
ation markedly impairs [PSI+] propagation. As expected, forced methylation of U1757 known to induce growth 
defect in yeast33 and of catalytic adenine A2820, caused major growth interference and no transformants were 
obtained. [PSI+] instability in PFAR-snoRNA-U2862 expressing cells was not due to modification of the 25S:18S 
ratio (Fig. 3D)35 or to onset of cellular stress (induction of Hsp104p or Hsp70p expression, Fig. 3E). It is difficult 
to prove that the targeted nucleotide is methylated32,35, but it is highly likely that [PSI+] loss on expression of 
PFAR-snoRNA-U2862 was due to methylation rather than antisense interference33, as targeting methylation to 
the neighboring nucleotide G2863 caused no defect. These results thus clearly implicate PFAR in [PSI+] propa-
gation with, to our knowledge, the first in vivo evidence of a direct link between inhibition of ribosome-assisted 
folding and prion destabilization.
PFAR enrichment enables [PSI+] propagation despite reduced Hsp104p activity. PFAR involve-
ment in [PSI+] propagation resembles the role of Hsp104p in [PSI+] propagation, suggesting an interplay between 
Hsp104p and PFAR protein chaperone activities for [PSI+] propagation. This is supported by GdnHCl’s synergis-
tic antiprion activity with 6AP and GA10,13. In the course of the present study, we also observed that the Hsp104p 
inhibitor GdnHCl was less effective in curing [PSI+] in ltv1Δ and yar1Δ mutants (Fig. 2A, bottom right filters) 
compared to WT strain (Figure S3A), despite similar GdnHCl sensitivity (Fig. 2G). Thus we reckoned that PFAR 
enrichment may partly compensate for Hsp104p’s inability to ensure [PSI+] propagation in presence of GdnHCl. 
However, despite PFAR enrichment, [PSI+] was lost in ltv1Δ -hsp104Δ and yar1Δ -hsp104Δ strains (data not 
shown): i.e., the PFAR level reached in ltv1Δ and yar1Δ strains was insufficient to fully compensate for HSP104 
deletion. We thus propose a model where Hsp104p and ribosome protein folding activities function complemen-
tarily to maintain stable [PSI+] propagation (Figure S3B, panels a,b). According to this model, the reduction in 
either of the two chaperon activities should be compensated by enrichment of the other (Figure S3B, panels c,d). 
With such a model, [PSI+] propagation should be sustained despite PFAR enrichment if Hsp104p activity is 
reduced (Figure S3B, panel c). To test this, we first evaluated [PSI+] behavior in PFAR-enriched mutants with 
Hsp104p inhibited by GdnHCl. Unlike the complete cure of WT strain [PSI+] prion in presence of GdnHCl, 
Hsp104p inhibition by GdnHCl increased [PSI+] stability 8 to 10-fold in ltv1Δ and yar1Δ strains compared to 
untreated [PSI+] cells (Figs 4A and S4A). Thus, [PSI+] instability caused by PFAR enhancement is compensated 
by reduced Hsp104p activity.
We then created diploid [PSI+] strains haploinsufficient for HSP104 (i.e., in which one of the two HSP104 
copies was deleted, Fig. 4B): if PFAR enrichment compensates for partial loss of Hsp104p activity, [PSI+] should 
also be more stable in PFAR-enriched strains where one of the two HSP104 alleles was deleted. As expected, sim-
ilarly to haploid mutants, ltv1Δ /ltv1Δ and yar1Δ /yar1Δ diploid strains displayed a higher proportion of [psi− ] 
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red colonies than WT strain (Fig. 4B, panels a, c and e, and Figure S4A). The HSP104/hsp104Δ haploinsufficient 
[PSI+] strain produced many [psi− ] red and red/white sectored colonies (92.1%, strain b Fig. 4B,C): i.e., HSP104 
haploinsufficiency in WT [PSI+] strain massively impaired prion propagation, without altering Sup35p protein 
Figure 3. In vitro site-directed methylation of nucleotide U2862 belonging to PFAR active site impairs [PSI+] 
propagation. (A) Schematic structure of a canonical box C/D snoRNA. Members of the box C/D family contain 
a box C (UGAUGA) and box D (CUGA) positioned near the 5′ and 3′ termini respectively and brought closer 
by nearby short complementary sequences. Additional C- and D-like motifs (boxes C′ and D′ ) are present in the 
central region of many snoRNAs. Guiding 2′ -O-methylation involves base pairing of the 10- to 21-nucleotide-
long guide sequence positioned upstream of box D or D′ to the target rRNA, selecting the nucleotide positioned 5 
bases upstream of D/D′ box for methylation (m). (B) Alignment of domain V rRNA sequences from S. cerevisiae 
(Sc, CP006467, bases 2803–2989), Homo sapiens (Hs, M11167.1) and E. coli (Ec, CP007136.1) surrounding 
U2862 (yeast numbering). The black box corresponds to E. coli domain V nucleotides involved in interaction with 
protein substrates78, and the green box to nucleotides interacting with 6AP and GA antiprion drugs14. E. coli  
domain V nucleotides showing loss of in vitro protein folding activity when mutated are shown in red14. Gray 
highlighting: nucleotides subjected to site-directed methylation. (C) WT [PSI+] cells were transformed by 
plasmids expressing PFAR-snoRNA specifically forcing methylation of U2862 and G2863 nucleotides involved 
in PFAR (gray, panel B). Negative controls: an empty plasmid (p424-GPD) and plasmid encoding natural snR38 
snoRNA targeting G2811 and causing no phenotype. [PSI+] stability was assessed as the number of [psi− ] red or 
sectored colonies from [PSI+] cells as a percentage of total cells. Averages of 3 experiments including 3 technical 
repeats are shown, with error bars; bar height represents mean; t-test: **P < 0.001 versus cells transformed by 
empty plasmid. (D) Relative abundance of amplified 18S and 25S rRNA was calculated using RT q-PCR, with 
actin mRNA as control for normalization in WT [PSI+] cells transformed with empty vector or plasmids encoding 
snoRNAs targeting U2862 and G2863 nucleotides. (E) Abundance of Hsp104p and Hsp70p, the expression of 
which was not modified in cells expressing PFAR-snoRNA U2862. GAPDH was used as loading control.
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levels (Fig. 4D). PFAR-enriched ltv1Δ /ltv1Δ and yar1Δ /yar1Δ HSP104-haploinsufficient strains produced many 
white/red sectored [psi− ] colonies (~ 96% for ltv1Δ /ltv1Δ and yar1Δ /yar1Δ diploid strains, strains d and f on 
Figure 4. [PSI+] instability due to PFAR enrichment is counterbalanced by partial inhibition of Hsp104p 
activity. (A) [PSI+] stability in presence of GdnHCl was evaluated by scoring [psi− ] colonies on YPD medium 
supplemented with 0.5 mM GdnHCl as a percentage of total cells for WT, ltv1Δ and yar1Δ strains. Experiments 
were repeated twice. A representative assay including 10 technical repeats is shown with error bars. Bar height 
represents the mean; t-test: **P < 0.001 versus untreated or GdnHCl-treated WT strain. (B) [PSI+] stability in 
HSP104 haploinsufficient strains. WT diploid strains (HSP104/HSP104, LTV1/LTV1, YAR1/YAR1, panel a), 
HSP104 haploinsufficient diploid strain (HSP104/hsp104Δ , LTV1/LTV1, YAR1/YAR1, panel b), PFAR-enriched 
diploid strains (HSP104/HSP104, ltv1Δ /ltv1Δ , panel c and HSP104/HSP104, yar1Δ /yar1Δ , panel e) and HSP104 
haploinsufficient, PFAR-enriched diploid strains (HSP104/hsp104Δ , ltv1Δ /ltv1Δ , panel d and HSP104/hsp104Δ , 
yar1Δ /yar1Δ , panel f) were spread on YPD medium to analyze [PSI+] phenotypes. The proportion of red sectors 
in a colony is proportional to [PSI+] instability. Plain red and sectored colonies were scored as [psi− ]. According 
to observed phenotypes, sectored colonies were classified as white/red if they had a majority of white sectors, or 
red/white if a majority of red sectors. Red/white sectored colonies denote stronger [PSI+] instability than white/red. 
(C) Proportions of [psi− ] red, [psi− ] red/white sectored, [psi− ] white/red sectored and [PSI+] white colonies 
produced by [PSI+] white colonies of the diploid strains described in the 6 panels of Fig. 4B, on YPD. Percentages 
are indicated in histogram bars. Experiments were repeated 3 times. A representative assay including 10 technical 
repeats is shown. (D) Lysates of exponentially growing diploid yeast cells were analyzed by SDS-PAGE for the 
expression of Hsp104p, Sup35p and Hsp70p. α -Tubulin was used as a loading control. The quantity of Sup35p 
and Hsp70p was not modified in HSP104 haploinsufficient strains.
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Fig. 4B,C): i.e., [PSI+] loss was lower in HSP104-haploinsufficient strains where PFAR is enriched (strains d and 
f) than HSP104/HSP104 strains (strains c and e). Thus, PFAR enrichment sustained [PSI+] propagation when 
Hsp104p activity was at a level unable to efficiently maintain [PSI+] propagation (Figs 4B,C and S4A).
Hsp104p overexpression enables [PSI+] propagation when PFAR is reduced. As PFAR enrich-
ment compensates for Hsp104p deficiency, we investigated whether enhanced Hsp104p activity could compen-
sate for PFAR inhibition, as in our model (Figure S3B, panel d). It was recently shown that mild (39 °C) heat shock 
quickly induces Hsp104p overexpression and impairs [PSI+] segregation during cell division, due to imbalance 
between Hsp104p and other stress-inducible heat-shock proteins such as Hsp70p36. [PSI+] destabilization was 
maximal 30 min after heat shock when imbalance between Hsp104p and Hsps was at its peak36. Moderate heat 
shock induced early overexpression of Hsp104p and a delayed Hsp70 expression (Fig. 5A) and destabilized [PSI+] 
compared to non-shocked cells (Fig. 5B). In line with our hypothesis, [PSI+] stability in WT cells was less affected 
when cells were pre-treated with 6AP or both 6AP and GdnHCl (Figs 5C and S4B). [PSI+] was massively desta-
bilized in heat-shocked PFAR-enriched cells (Figs 5D,E and S4B) and 6AP treatment restored [PSI+] stability in 
synergy with GdnHCl in ltv1Δ and yar1Δ PFAR-enriched strains (Figs 5D,E and S4B): i.e., PFAR and Hsp104p 
Figure 5. PFAR inhibition compensates [PSI+] loss in cells overexpressing Hsp104p. (A) WT [PSI+] cells 
were submitted to 39 °C moderate heat shock. WT cells harvested at indicated times were lysed and proteins 
were immunoblotted using anti-Hsp104p and anti-Hsp70p antibodies. Anti-GAPDH antibodies were used 
as a loading control. These data are representative of 3 different experiments. (B) WT cells harvested at 
indicated times were spread on YPD medium to score [psi− ] colonies. Experiments were repeated 3 times. A 
representative assay including 6 technical repeats is shown with error bars. Bar height represents the mean; 
t-test: **P < 0.001. (C–E) [PSI+] stability increases in heat-shock cells treated by 6AP, GdnHCl or both. WT 
[PSI+] cells (C), ltv1Δ [PSI+] cells (D) and yar1Δ [PSI+] cells (E) were pretreated by DMSO, 100 μ M 6AP (WT) 
or 300 μ M 6AP (ltv1Δ and yar1Δ ), 1 mM GdnHCl or by 6AP + GdnHCl before 39 °C heat shock. Aliquots 
were collected at indicated incubation times, cells were spread on YPD plates and [PSI+] stability was evaluated 
by scoring [psi− ] red or sectored colonies as percentage of total plated cells for untreated and 6AP-, GdnHCl-, 
6AP- and GdnHCl-treated cells not heat-shocked. Experiments were repeated 3 times. A representative assay 
including 5 technical repeats is shown with error bars. Bar height represents the mean; t-test: *P < 0.05 or 
**P < 0.001 versus untreated strains.
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compensate each other for efficient [PSI+] propagation. Thus, a delicate balance between Hsp104p and PFAR 
chaperone activities appears necessary to maintain [PSI+] propagation (Figure S3B).
Discussion
The present results are, to our knowledge, the first evidence of a direct link between PFAR, the protein folding 
activity of the ribosome, and [PSI+] propagation, and are a major breakthrough in understanding the conserved 
cellular mechanisms governing prion propagation and spontaneous appearance. Although the primary role of 
chaperones is to prevent protein misfolding and aggregation, involvement of cell chaperones like Hsp104p and 
PFAR in the propagation of a prion conformation is self-evident, as prion-forming proteins exist in several con-
formations and replication corresponds to propagation of differentially folded states5. Despite we cannot exclude 
that the action of PFAR may be indirect, [PSI+] loss was not a consequence of Hsp70 disturbance (Fig. 2G).
That [PSI+] is impaired when PFAR is inhibited or strengthened is reminiscent of Hsp104p’s involvement 
in prion propagation in yeast, just as [PSI+] propagation is impaired by both Hsp104p inhibition and overex-
pression. Like Hsp104p, domain V of the ribosome may have chaperone activity able to deal with cross-β sheet 
amyloid aggregates37 since reduced Hsp104p activity, deleterious for [PSI+] propagation, is compensated for by 
enriched PFAR activity, and vice versa (Figs 4 and 5). This interplay between PFAR and Hsp104p for [PSI+] prop-
agation is in good agreement with GdnHCl’s synergistic effect with 6AP or GA in curing [PSI+] from yeast10,13.
That PFAR enrichment enhanced de novo [PSI+] formation (Fig. 2H) is similar to Hsp104p function, which 
greatly accelerates polymerization of the prion-forming domain (fragment NM) of Sup35 into amyloid fibers 
when added at sub-stoichiometric concentrations in vitro38. PFAR enrichment impairs [PSI+] propagation but 
boosts [PSI+] de novo formation, and indeed the two involve different mechanisms39. Neither GdnHCl nor excess 
Hsp104p, both known to impair [PSI+] propagation, prevents de novo appearance of [PSI+] by Sup35p overex-
pression in [psi− ] strains. The fact that rRNA has previously been found associated to PrPSc fits nicely with our 
finding that PFAR is involved in de novo appearance of [PSI+]40. Thus, PFAR may well be involved in de novo 
formation of [PSI+], for which Hsp104p is not essential in vivo39,41.
Protein folding associated with an rRNA molecule furthers the list of ribozymes and non-coding RNAs serv-
ing a wide variety of biological functions42. There is now much evidence that PFAR may be an ancestral protein 
chaperone activity pre-dating the well-known protein-based chaperone Hsp104p disaggregase activity17. The 
“RNA world” hypothesis suggests that, prior to protein synthesis, catalytic functions were carried out by RNA 
molecules, with DNA and protein-based life developing later43. The universality of the antiprion effect of 6AP 
and GA, active both in yeast and mammals, is due to ribosome structure and function conservation throughout 
evolution, especially domain V of the large rRNA44. As there is no Hsp104p ortholog in mammals, and all three 
antiprion drugs 6AP, GA and IQ are active against both yeast and mammalian prions, it is tempting to speculate 
that PFAR is involved in prion formation and propagation in mammals. Of note, due to the localization of the 
ribosome, PFAR may only be involved in the propagation of cytosolic prions.
Although the actual cellular role of PFAR remains unclear, it may contribute to a wide variety of cell func-
tions. Its potential in vivo importance in a variety of cell processes is highlighted by its chaperone activity on a 
wide range of protein substrates in vitro17. In previous reports, the bacterial ribosome showed general chaperone 
activity, acting as a holdase to prevent aggregation of denatured proteins and improve their folding37. Our basal 
thermotolerance and luciferase refolding assays in yeast clearly showed that, in absence of Hsp104p activity, PFAR 
efficiently participates in refolding proteins damaged by heat shock and in cell survival (Fig. 1B–E).
Thus, in addition to being directly involved in prion propagation, PFAR can also handle stress-induced pro-
tein aggregates and partly compensate for the absence of Hsp104p (Fig. 1). On the one hand, Hsp104p’s disag-
gregase activity confers a capacity to handle amyloid aggregates that is lacking in bacteria ClpB itself4. On the 
other hand, its capacity to deal with disordered aggregates is less than that of ClpB4; loss of this may have been 
viable as the ribosome possesses a compensatory activity of unknown nature. Together with Hsp104p and PFAR, 
yeast cells possess partly redundant disaggregase activities to efficiently handle stress-induced aggregates and 
tolerate amyloids. The absence of Hsp104-like disaggregase activity in multicellular organisms is likely due to 
stem-metazoan lineage gene loss preceding evolution of the gastrulation process45. This is particularly perplexing 
as the metazoan protein-based disaggregase system - Hsp110, Hsp70 and Hsp40 - cannot rapidly disaggregate 
amyloids46, even though some small heat-shock proteins can potentiate their amyloid-depolymerizing activity47. 
The recent identification of RuvbL1 and RuvbL2 disaggregases may shed a new light on this field48. As metazoa 
have no Hsp104p-like disaggregase activity, some groups explored reinforcing the metazoan cell proteostasis 
network with Hsp104p to help overcome the toxicity of amyloid-forming proteins. Hsp104p overexpression 
reduced aggregate formation in yeast49, C. elegans50, Drosophila51 and human cell lines52, and increased nerve-cell 
stress tolerance53, reduced polyglutamine aggregation and prolonged survival in transgenic mouse models of 
Huntington’s54 and Parkinson’s diseases55. Hsp104p may have evolved its operational plasticity in order to tol-
erate prions, possession of which confers selective advantage to cells in some conditions4,56. We can now extend 
this hypothesis: the ribosome may have retained RNA-based protein chaperone activity to compensate for the 
lack of protein-based Hsp104p-like disaggregase activity in bacteria and metazoan, and PFAR was maintained 
or evolved in yeast to combine with Hsp104p to take advantage of the numerous amyloid-prone proteins57. The 
protein folding activity of domain V of the ribosome might correspond to the Hsp104-like activity responsi-
ble for amyloid handling that is absent in metazoa. This hypothesis, while speculative, makes sense in light of 
recent findings that some antiprion compounds with anti-PFAR activity are also active in models of other protein 
aggregation-based diseases, where etiology is likely overlapping58,59: e.g., 6AP & GA interfered with aggrega-
tion cell-based models of Huntington’s disease (M. Blondel & A. Bertolotti, European patent application) and 
yeast-based models for Huntington’s and Parkinson’s disease (CV, JE, MB, unpublished data). Also, 6AP & GA 
showed benefit in a Drosophila-based model of OPMD (Oculopharyngeal muscular dystrophy), an inherited 
dominant myodegenerative disease caused by extension of a polyalanine tract in PABPN1 protein resulting in 
www.nature.com/scientificreports/
1 0Scientific RepoRts | 6:32117 | DOI: 10.1038/srep32117
amyloid fiber accumulation19. Remarkably, synergy was observed between smaller deletions of rRNA encoding 
locus, which have no effect on OPMD phenotype, and sub-effective concentrations of 6AP & GA. Both increasing 
and decreasing the level of PFAR, a natural eukaryotic cell protein chaperone activity, may thus offer a new ther-
apeutic avenue in some amyloid-based diseases.
Methods
Yeast strains and genetic manipulations. The yeast strain used in this study was 74-D694 WT [PSI+] 
weak (Mata, ade1-14, trp1-289, his3Δ 200, ura3-52, leu2-3,112)10,60,61. Yeasts were grown and used as previously 
described60. As for PrP, various strains of yeast prions have also been described. They are based on the same prion 
protein but present different biological or biochemical properties due to structural differences1,62. Strong [PSI+] 
variant has a larger proportion of aggregated Sup35p than the weak variant, thus allowing a more efficient trans-
lational read-through than the weak variant, which is therefore pinker1. As the overall stability of strong [PSI+] 
variant is higher than the stability of the weak variant, our experiments were performed with weak [PSI+] variant, 
in which [PSI+] destabilization (appearance of [psi− ] red colonies) was easier to detect.
Standard genetic manipulations were as described63. Mutant ltv1Δ , yar1Δ , hsp104Δ and rpl8aΔ strains were 
constructed by replacing, in 74-D694 weak [PSI+], WT genes by PCR-amplified of the heterologous Escherichia 
coli kanr or Schizosaccharomyces pombe his5+ genes as selection markers64 using the primers described in Table 
S1, designed to replace the entire coding region of LTV1, YAR1, HSP104 and RPL8A genes from ATG to stop 
codon. ltv1Δ strain (ltv1::KanMx) was constructed by replacing LTV1 gene by kanr marker using LTV1-F and 
LTV1-R primers. yar1Δ [PSI+] strain (yar1::his5) was constructed by replacing YAR1 gene by his5+ marker using 
primers YAR1-F and YAR1-R. hsp104Δ -K and hsp104Δ -H strains were constructed by replacing HSP104 gene 
by either kanr (hsp104::KanMx) or his5+ (hsp104::his5) markers, respectively, using HSP104-F and HSP104-R 
primers. rpl8aΔ strain (rpl8a::KanMx) was constructed by replacing RPL8A gene by kanr marker using RPL8A-F 
and RPL8A-R primers. After transformation of yeast cells with the deletion cassette by the lithium acetate pro-
cedure, a successful gene replacement was demonstrated by analytical PCR on genomic DNA using LTV1-Fbis 
and LTV1-Rbis, YAR1-Fbis and YAR1-Rbis, HSP104bis-F and HSP104bis-R, and RPL8Abis-F and RPL8Abis-R 
primers (Table S1).
WT diploid strain (HSP104/HSP104, LTV1/LTV1, YAR1/YAR1), HSP104 haploinsufficient diploid strain 
(HSP104/hsp104Δ , LTV1/LTV1, YAR1/YAR1), PFAR enriched diploid strains (HSP104/HSP104, ltv1Δ /ltv1Δ and 
HSP104/HSP104, yar1Δ /yar1Δ ) and PFAR enriched HSP104 haploinsufficient diploid strains (HSP104/hsp104Δ 
ltv1Δ /ltv1Δ and HSP104/hsp104Δ , yar1Δ /yar1Δ ) were obtained by mating HSP104, hsp104::KanMx, 
hsp104::his5, ltv1::KanMx and yar1::his5 haploid strains described above. ltv1Δ /rpl8aΔ and yar1Δ /rpl8aΔ 
strains were obtained by mating ltv1::KanMx, yar1::his5 and rpl8a::KanMx haploid strains described above.
Mutant yar1Δ NT64 [URE3] strain was constructed by replacing, in NT64 [URE3] (MATα, trp1-1, ade2-1, 
his3-11,15, leu2-3,112, ura3-1, pdal5::ADE2)10, YAR1 gene by his5+ marker64 using primers YAR1-F and YAR1-R 
described in Table S1.
BMS165 complete ORF (YPL217C) cloned in Gateway vector under GAL1 promoter (Open Biosytems, plas-
mid 28A6) came from the Yeast ORF collection of E. Phizicky and M. Snyder66. Bms1p expression was induced 
on medium containing 2% galactose and 2% raffinose. pDCM90 plasmid (gift by D. Masison) allows constitutive 
expression of a temperature-sensitive luciferase polypeptide67.
Basal thermotolerance. [psi− ] WT, ltv1Δ , yar1Δ , hsp104Δ , hsp104Δ /ltv1Δ and hsp104Δ /yar1Δ 74-D694 
strain cells were grown in liquid YPD medium at 29 °C and exponentially growing cells were diluted to 2,500 cells/
ml. Cultures were split into 2 samples and moved to 29 °C (no heat shock) and to 47 °C (heat shock). Aliquots 
were taken after specified periods and cells were spread for viability onto YPD medium and incubated at 29 °C 
for 5 days68. Viability was monitored as the number of surviving heat shocked cells versus cells left at 29 °C for 
each strain.
In vivo luciferase refolding assay. [psi− ] WT, ltv1Δ , yar1Δ , hsp104Δ , hsp104Δ /ltv1Δ and hsp104Δ 
/yar1Δ 74-D694 strains were transformed with pDCM90 plasmid69,70, allowing constitutive expression of 
temperature-sensitive luciferase polypeptide. Heat-inactivated luciferase activity was monitored as described 
in ref. 71. Briefly, transformants were exponentially grown at 29 °C. Cells were pretreated for 30 min at 37 °C 
to induce expression of heat-shock proteins. Cells were treated with 200 μ M 6AP or DMSO before heat-shock. 
Luciferase was then heat-inactivated by incubation at 45 °C for 60 min or kept at 29 °C for 60 min as control 
(pre-heat-shock). 10 μ g/mL cycloheximide (Sigma Aldrich) was added after 50 min at 45 °C to arrest luciferase 
synthesis during recovery. Luciferase activity was immediately measured after 60 min of heat-shock at 45 °C 
(0 min) and cells were then left to recover at 25 °C for indicated periods, luciferase activity being assessed at 
30 min intervals by adding 10 μ l n-decylaldehyde (Sigma Aldrich) to 200 μ L yeast culture. Luminescence was 
quantified using a Varioscan microplate reader (ThermoFisher). Luciferase activity was then expressed as a per-
centage of the activity before the 45 °C heat treatment for each strain.
Polysome gradients. A total of 18 OD600 of exponentially growing yeast cells were treated for 10 min with 
10 μ g/ml of cycloheximide, harvested by centrifugation, and washed cell pellets were resuspended in 150 μ l lysis 
buffer (10 mM Tris-HCl pH 7.5, 100 mM NaCl, 30 mM MgCl2, 200 μ g/mL heparin, 10 μ g/mL cycloheximide, 
1 mM DTT, 40 U/mL RNase inhibitor, antiprotease cocktail (Roche), in DEPC-treated water). After the addition 
of 425–600 μ m glass beads (Sigma Aldrich), cells were lysed by the alternating of 6 vortexing and ice-cooling steps 
of 30 sec each and then centrifuged for 5 min at 2,300 g at 4 °C. Supernatants were recovered, centrifuged at 9,300 g 
for 10 min at 4 °C and assayed for RNA content at OD260. 100 U OD260 of RNA were loaded on top of 10–40% 
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sucrose gradients, centrifuged for 3h at 41,600 rpm using a SW55ti swing rotor (Beckman coulter). 200 μ L 
fractions were collected, and OD260 was measured on 1/10 diluted fractions26,72.
Pulse chase. 5 ml of exponentially growing cultures of WT, ltv1Δ and yar1Δ [PSI+] cells were grown in 
presence of radiolabeled [35S] methionine (PerkinElmer Life Sciences) for 10 min, and then chased in medium 
containing 50 mM cold methionine for 15 min before harvesting. Protein extracts were prepared as described 
above and analyzed by 2D-gel electrophoresis followed by autoradiography.
Electrophoresis, western blot and antibodies. A total of 6 OD600 of exponentially growing yeast cells 
were harvested by centrifugation and cell pellets were resuspended in lysis buffer (25 mM Tris-HCl pH 7.4, 
100 mM NaCl, 0.2% Triton X-100, antiprotease cocktail (Roche), 1 mM phenyl-methylsulfonyl fluoride). After 
the addition of 425–600 μ m acid-washed glass beads (Sigma Aldrich), cells were lysed by the alternating of six 
vortexing and ice-cooling steps for 30 sec each and then centrifuged for 3 min at 800 g at 4 °C. Supernatants were 
recovered and assayed for protein content. Protein extracts were analysed by 10% SDS-PAGE (precast NuPAGE, 
Invitrogen) and transferred to 0.45 μ m nitrocellulose membranes (Whatman). Membranes were blocked with 
PBS 1X/0.1% Igepal containing 5% fat-free milk and 0.5% BSA, and incubated overnight at 4 °C using 1/1,000 
rabbit anti-Sup35p serum (made by Eurogentec according to73), 1/10,000 mouse monoclonal anti-Hsp104p (kind 
gift of J. Glover, Montreal), 1/5,000 anti-HA (Clontech, cat. 631207), 1/5,000 mouse anti-Actin (Calbiochem, cat. 
CP01), 1/2,500 mouse anti-Hsp70/Hsc70 (Stressgen, cat. ADI-SPA-822-D), or 1/5,000 anti-GAPDH (Abcam, cat. 
ab125247). The membranes were then washed with fresh PBS 1X/0.1% Igepal and incubated for 45 min with sec-
ondary antibodies (goat anti-rabbit or goat anti-mouse, Biorad; goat anti-mouse IgM, Calbiochem) conjugated to 
horseradish peroxydase at a 1/3000 dilution, and analysed by Enhanced Chemiluminescence (ECL, Amersham) 
using Vilber-Lourmat Photodocumentation Chemistart 5000 imager.
Yeast-based antiprion assay. An aliquot of exponentially growing cultures (170 μ l of 0.5 OD600 culture of 
WT [PSI+] and 340 μ L of 0.5 OD600 culture of ltv1Δ and yar1Δ [PSI+] strains) was homogeneously spread using 
sterile glass beads (≈ 3 to 5 mm diameter) on square (12 cm × 12 cm) Petri plates containing YPD solid medium 
supplemented with 200 μ M GdnHCl, as previously described10,60. GdnHCl and guanabenz were purchased from 
Sigma Aldrich. Small sterile filters (Thermo-Fisher) were then placed on the agar surface and individual com-
pounds were applied to each filter. DMSO, the vehicle, was applied to the top left filter as a negative control, and 
GdnHCl solubilized in water was applied to the bottom right filter as a positive control. The Petri plates were then 
incubated for four days at 25 °C and scanned using Snap Scan1212 (Agfa). In [psi− ] cells, Sup35p is in a soluble 
form and causes the ribosome to stop translation at stop codons, including the premature stop codon present 
in the ade1-14 allele of the ADE1 gene. This leads to the production of a truncated and non-functional Ade1 
protein, thus preventing cells to grow on medium lacking adenine and leading to the formation of red colonies 
on rich YPD medium because cells accumulate an intermediate metabolite of the adenine biosynthesis pathway 
(for review see1). When most of Sup35p is sequestrated under certain forms of amyloid, it cannot function effi-
ciently in its normal role of translation termination, thus leading to an increased tendency of the ribosome to read 
through stop codons, including the premature stop codon in the ade1-14 allele of ADE1 gene1,74. Consequently, 
in cells harboring the ade1-14 genotype, a functional Ade1p enzyme is produced in [PSI+] cells, allowing cells 
to form white or pink colonies on YPD rich medium. Thus, when a compound is active against [PSI+] prion, a 
halo of red colonies appears around the filter where it was spotted, whereas colonies remain white in the case of 
inactive compounds.
Prion stability. 50–100 cells from [PSI+] exponentially growing cultures were spread on ten YPD plates with 
specified drug concentrations and incubated at 29 °C. Following colony formation, [PSI+] loss was monitored as 
the percentage of red and sectored [psi− ] colonies. Comparisons between strains and/or conditions were always 
performed within the same experiment.
Frequency of spontaneous conversion from [psi−] to [PSI+]. The de novo formation of [PSI+] from 
[psi− ] cells was monitored on media deprived of adenine where [PSI+] appearance was scored as growth, as 
previously described41,75,76. We used [psi− ] [PIN+] cells for this set of experiment as [PIN+], the prion form of 
Rnq1 protein, is needed for [PSI+] de novo formation77. 3 million cells from exponentially growing cultures 
(0.8 OD600 cultures) of WT, ltv1Δ and yar1Δ [psi− ] [PIN+] strains were spread on synthetic medium lacking 
adenine (SD-Ade) and grown for 2 weeks at 29 °C. To distinguish [PSI+] colonies from chromosomal suppressor 
mutations, Ade+ colonies were subjected to treatment with 2 mM GdnHCl antiprion drug as genuine white/pink 
[PSI+] cells switch to [psi− ] red cells when [PSI+] is cured by GdnHCl, whereas Ade+ spontaneous mutants keep 
a white color in presence of GdnHCl41. The number of colonies that underwent a colour change was scored for 
each replica plate. The total number of cells really spread was determined by plating, onto rich YPD medium, 
100 μ L of a 1/40,000 dilution of the same [psi− ] [PIN+] cultures that were spread on SD-Ade.
snoRNA site-directed methylation of rRNA. Some specific nucleotides of domain V of bacteria 
23S rRNA were recently shown to specifically interact with denatured proteins under the refolding process78. 
Some of these nucleotides were also shown to interact with 6AP and GA, two drugs that display anti-PFAR and 
anti-prion activities79. The mutation of some of these nucleotides of bacterial 23S rRNA led to a complete loss of 
the refolding activity of domain V and completely abolished the interaction of 6AP and GA with rRNA at these 
positions79. The mutation of the corresponding nucleotides on domain V of yeast 25S rRNA also abolished its 
protein folding activity in vitro79. snoRNAs we used correspond to RNA moiety of snoRNA:protein complexes, 
named box C/D snoRNPs (small nucleolar RiboNucleoParticles), that are involved in 2′ -O-methylation required 
for post-transcriptional maturation of rRNAs and other RNA produced in the nucleolus80,81. The specific guide 
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sequence of snR38 (plasmid pBL15033) was replaced by a 14 nucleotides sequence targeting one of the nucleo-
tides of 25S domain V we identified as involved in PFAR (see above)79. Primers were designed to create snoR-
NAs specifically targeting nucleotides U2862 and G2863 of domain V of rRNA 25S (PFAR-snoRNAs; Table S1). 
PFAR-snoRNAs were amplified from plasmid pBL14333 using each specific primer and BLO-38 primer (Table S1). 
PFAR-snoRNAs PCR products were digested by BglII and NdeI and cloned into pBL15033. PFAR-snoRNAs 
were then subcloned into p424 plasmid using BamHI and SacI restriction enzymes under the control of the 
strong constitutive GPD promoter. WT weak [PSI+] yeast cells were transformed by either p424-GPD encoding 
PFAR-snoRNAs, empty p424-GPD plasmid, or pBL150 plasmid encoding natural yeast snoRNA snR38 targeting 
G2811 as negative controls33. [PSI+] stability was then scored on YPD. snoRNAs targeting the catalytic adenine 
A2820 and U1757 on 18S rRNA (plasmid pBL143 encoding a snoRNA that has been shown to target a nucleotide 
essential for protein synthesis33), were used as positive controls inducing cell death (data not shown). Note that 
neither U2862 nor G2863 nucleotides of yeast 25S rRNA targeted by our custom PFAR-snoRNAs carry a natural 
post-translational modification34.
RT Q-PCR. Total yeast cellular RNAs were extracted by RNAeasy and RNase-free DNase kits (QIAGEN). 
cDNA was synthesized from 1 μ g DNA-free RNA by Superscript II (Invitrogen) using 18S-F, 25S-F and Actin-F 
primers (Table S1). cDNA samples underwent qPCR with 18S-F/18S-R, 25S-F/25S-R and Actin-F/Actin-R prim-
ers (Table S1), using the QuantiTect SYBR Green PCR kit (Qiagen) in Abiprism 7000 Sequence Detection System 
(Applied).
Prion stability after moderate heat shock. WT, ltv1Δ and yar1Δ [PSI+] cells were grown in liquid 
YPD medium overnight at 29 °C and diluted to OD600 = 0.1, followed by incubation at 29 °C in presence of 6AP 
(1h at 300 μ M for ltv1Δ and yar1Δ strains or 100 μ M for WT strain), GdnHCl (15 min at 1 mM) or both 6AP and 
GdnHCl. Cultures were then shifted to 39 °C. Aliquots were taken after specified periods. Serial dilutions were 
prepared to plate 50 to 100 cells onto YPD solid medium and incubated at 29 °C36.
References
1. Liebman, S. W. & Chernoff, Y. O. Prions in yeast. Genetics 191, 1041–1072, doi: 10.1534/genetics.111.137760 (2012).
2. Wickner, R. B. [URE3] as an altered URE2 protein: evidence for a prion analog in Saccharomyces cerevisiae. Science 264, 566–569 
(1994).
3. Winkler, J., Tyedmers, J., Bukau, B. & Mogk, A. Chaperone networks in protein disaggregation and prion propagation. J Struct Biol 
179, 152–160, doi: 10.1016/j.jsb.2012.05.002 (2012).
4. DeSantis, M. E. et al. Operational plasticity enables hsp104 to disaggregate diverse amyloid and nonamyloid clients. Cell 151, 
778–793, doi: 10.1016/j.cell.2012.09.038 (2012).
5. Jones, G. W. & Tuite, M. F. Chaperoning prions: the cellular machinery for propagating an infectious protein? Bioessays 27, 823–832, 
doi: 10.1002/bies.20267 (2005).
6. Doyle, S. M., Genest, O. & Wickner, S. Protein rescue from aggregates by powerful molecular chaperone machines. Nat Rev Mol Cell 
Biol 14, 617–629, doi: 10.1038/nrm3660 (2013).
7. Wickner, R. B. et al. Amyloids and yeast prion biology. Biochemistry 52, 1514–1527, doi: 10.1021/bi301686a (2013).
8. Helsen, C. W. & Glover, J. R. Insight into molecular basis of curing of [PSI+ ] prion by overexpression of 104-kDa heat shock protein 
(Hsp104). J Biol Chem 287, 542–556, doi: 10.1074/jbc.M111.302869 M111.302869 [pii] (2012).
9. Park, Y. N. et al. Hsp104 overexpression cures Saccharomyces cerevisiae [PSI+ ] by causing dissolution of the prion seeds. Eukaryot 
Cell 13, 635–647, doi: 10.1128/EC.00300-13 (2014).
10. Bach, S. et al. Isolation of drugs active against mammalian prions using a yeast-based screening assay. Nat Biotechnol 21, 1075–1081 
(2003).
11. Tribouillard-Tanvier, D. et al. Protein folding activity of ribosomal RNA is a selective target of two unrelated antiprion drugs. PLOS 
One 3, e2174 (2008).
12. Oumata, N. et al. The toll-like receptor agonist imiquimod is active against prions. PLoS One 8, e72112, doi: 10.1371/journal.
pone.0072112 (2013).
13. Tribouillard-Tanvier, D. et al. Antihypertensive drug guanabenz is active in vivo against both yeast and mammalian prions. PLoS 
One 3, e1981 (2008).
14. Pang, Y. et al. The antiprion compound 6-aminophenanthridine inhibits the protein folding activity of the ribosome by direct 
competition. J Biol Chem 288, 19081–19089, doi: 10.1074/jbc.M113.466748 (2013).
15. Chattopadhyay, S., Das, B. & Dasgupta, C. Reactivation of denatured proteins by 23S ribosomal RNA: role of domain V. Proc Natl 
Acad Sci USA 93, 8284–8287 (1996).
16. Banerjee, D. & Sanyal, S. Protein Folding Activity of the Ribosome (PFAR)—A Target for Antiprion Compounds. Viruses 6, 
3907–3924, doi: v6103907 (2014).
17. Das, D. et al. Role of the ribosome in protein folding. Biotechnol J 3, 999–1009, doi: 10.1002/biot.200800098 (2008).
18. Voisset, C., Thuret, J. Y., Tribouillard-Tanvier, D., Saupe, S. J. & Blondel, M. Tools for the study of ribosome-borne protein folding 
activity. Biotechnol J 3, 1033–1040, doi: 10.1002/biot.200800134 (2008).
19. Barbezier, N. et al. Antiprion drugs 6-aminophenanthridine and guanabenz reduce PABPN1 toxicity and aggregation in 
oculopharyngeal muscular dystrophy. EMBO Mol Med 3, 35–49, doi: 10.1002/emmm.201000109 (2011).
20. Reis, S. D. et al. Mode of action of the antiprion drugs 6AP and GA on ribosome assisted protein folding. Biochimie 93, 1047–1054, 
doi: S0300-9084(11)00074-5 (2011).
21. Das, B., Chattopadhyay, S., Bera, A. K. & Dasgupta, C. In vitro protein folding by ribosomes from Escherichia coli, wheat germ and 
rat liver: the role of the 50S particle and its 23S rRNA. Eur J Biochem 235, 613–621 (1996).
22. Mondal, S., Pathak, B. K., Ray, S. & Barat, C. Impact of P-Site tRNA and antibiotics on ribosome mediated protein folding: studies 
using the Escherichia coli ribosome. PLoS One 9, e101293, doi: 10.1371/journal.pone.0101293 (2014).
23. Basu, A. et al. Protein folding following synthesis in vitro and in vivo: association of newly synthesized protein with 50S subunit of 
E. coli ribosome. Biochem Biophys Res Commun 366, 592–597, doi: S0006-291X(07)02585-5 (2008).
24. Chattopadhyay, S., Das, B., Bera, A. K., Dasgupta, D. & Dasgupta, C. Refolding of denatured lactate dehydrogenase by Escherichia 
coli ribosomes. Biochem J 300 (Pt 3), 717–721 (1994).
25. Koch, B. et al. Yar1 protects the ribosomal protein Rps3 from aggregation. J Biol Chem 287, 21806–21815, doi: 10.1074/jbc.
M112.365791 (2012).
26. Loar, J. W. et al. Genetic and biochemical interactions among Yar1, Ltv1 and Rps3 define novel links between environmental stress 
and ribosome biogenesis in Saccharomyces cerevisiae. Genetics 168, 1877–1889, doi: 168/4/1877 (2004).
www.nature.com/scientificreports/
13Scientific RepoRts | 6:32117 | DOI: 10.1038/srep32117
27. Merwin, J. R. et al. Genetic analysis of the ribosome biogenesis factor Ltv1 of Saccharomyces cerevisiae. Genetics 198, 1071–1085, 
doi: 10.1534/genetics.114.168294 (2014).
28. Voisset, C., Saupe, S. J., Galons, H. & Blondel, M. Procedure for identification and characterization of drugs efficient against 
mammalian prion: from a yeast-based antiprion drug screening assay to in vivo mouse models. Infect Disord Drug Targets 9, 31–39 
(2009).
29. Bonander, N. et al. Altering the ribosomal subunit ratio in yeast maximizes recombinant protein yield. Microb Cell Fact 8, 10, doi: 
10.1186/1475-2859-8-10] (2009).
30. Ohtake, Y. & Wickner, R. B. Yeast virus propagation depends critically on free 60S ribosomal subunit concentration. Mol Cell Biol 
15, 2772–2781 (1995).
31. Jones, G. W., Song, Y. & Masison, D. C. Deletion of the Hsp70 chaperone gene SSB causes hypersensitivity to guanidine toxicity and 
curing of the [PSI+ ] prion by increasing guanidine uptake in yeast. Mol Genet Genomics 269, 304–311, doi: 10.1007/s00438-003-
0838-y (2003).
32. Decatur, W. A., Liang, X. H., Piekna-Przybylska, D. & Fournier, M. J. Identifying effects of snoRNA-guided modifications on the 
synthesis and function of the yeast ribosome. Methods Enzymol 425, 283–316, doi: S0076-6879(07)25013-X (2007).
33. Liu, B. & Fournier, M. J. Interference probing of rRNA with snoRNPs: a novel approach for functional mapping of RNA in vivo. RNA 
10, 1130–1141, doi: 10.1261/rna.7190104 (2004).
34. Piekna-Przybylska, D., Decatur, W. A. & Fournier, M. J. The 3D rRNA modification maps database: with interactive tools for 
ribosome analysis. Nucleic Acids Res 36, D178–D183, doi: gkm855 (2008).
35. Liu, B., Liang, X. H., Piekna-Przybylska, D., Liu, Q. & Fournier, M. J. Mis-targeted methylation in rRNA can severely impair 
ribosome synthesis and activity. RNA Biol 5, (2008).
36. Newnam, G. P., Birchmore, J. L. & Chernoff, Y. O. Destabilization and recovery of a yeast prion after mild heat shock. J Mol Biol 408, 
432–448, doi: 10.1016/j.jmb.2011.02.034 (2011).
37. Pathak, B. K., Mondal, S., Ghosh, A. N. & Barat, C. The ribosome can prevent aggregation of partially folded protein intermediates: 
studies using the Escherichia coli ribosome. PLoS One 9, e96425, doi: 10.1371/journal.pone.0096425 (2014).
38. Shorter, J. & Lindquist, S. Hsp104 catalyzes formation and elimination of self-replicating Sup35 prion conformers. Science 304, 
1793–1797, doi: 10.1126/science.1098007 (2004).
39. Zhou, P., Derkatch, I. L. & Liebman, S. W. The relationship between visible intracellular aggregates that appear after overexpression 
of Sup35 and the yeast prion-like elements [PSI(+ )] and [PIN(+ )]. Mol Microbiol 39, 37–46, doi: mmi2224 (2001).
40. Lathe, R. & Harris, A. Differential display detects host nucleic acid motifs altered in scrapie-infected brain. J Mol Biol 392, 813–822, 
doi: 10.1016/j.jmb.2009.07.045 (2009).
41. Derkatch, I. L., Chernoff, Y. O., Kushnirov, V. V., Inge-Vechtomov, S. G. & Liebman, S. W. Genesis and variability of [PSI] prion 
factors in Saccharomyces cerevisiae. Genetics 144, 1375–1386 (1996).
42. Cech, T. R. & Steitz, J. A. The noncoding RNA revolution-trashing old rules to forge new ones. Cell 157, 77–94, doi: 10.1016/j.
cell.2014.03.008 (2014).
43. Joyce, G. F. The antiquity of RNA-based evolution. Nature 418, 214–221, doi: 10.1038/418214a (2002).
44. Melnikov, S. et al. One core, two shells: bacterial and eukaryotic ribosomes. Nat Struct Mol Biol 19, 560–567, doi: 10.1038/nsmb.2313 
(2012).
45. Erives, A. J. & Fassler, J. S. Metabolic and chaperone gene loss marks the origin of animals: evidence for hsp104 and hsp78 
chaperones sharing mitochondrial enzymes as clients. PLoS One 10, e0117192, doi: 10.1371/journal.pone.0117192 (2015).
46. Shorter, J. The mammalian disaggregase machinery: Hsp110 synergizes with Hsp70 and Hsp40 to catalyze protein disaggregation 
and reactivation in a cell-free system. PLoS One 6, e26319, doi: 10.1371/journal.pone.0026319 (2011).
47. Duennwald, M. L., Echeverria, A. & Shorter, J. Small heat shock proteins potentiate amyloid dissolution by protein disaggregases 
from yeast and humans. PLoS Biol 10, e1001346, doi: 10.1371/journal.pbio.1001346 (2012).
48. Zaarur, N. et al. RuvbL1 and RuvbL2 enhance aggresome formation and disaggregate amyloid fibrils. EMBO J 34, 2363–2382, doi: 
10.15252/embj.201591245 (2015).
49. Krobitsch, S. & Lindquist, S. Aggregation of huntingtin in yeast varies with the length of the polyglutamine expansion and the 
expression of chaperone proteins. Proc Natl Acad Sci USA 97, 1589–1594, doi: 97/4/1589 (2000).
50. Satyal, S. H. et al. Polyglutamine aggregates alter protein folding homeostasis in Caenorhabditis elegans. Proc Natl Acad Sci USA 97, 
5750–5755, doi: 10.1073/pnas.100107297 (2000).
51. Cushman-Nick, M., Bonini, N. M. & Shorter, J. Hsp104 suppresses polyglutamine-induced degeneration post onset in a drosophila 
MJD/SCA3 model. PLoS Genet 9, e1003781, doi: 10.1371/journal.pgen.1003781 PGENETICS-D-13-00866 (2013).
52. Perrin, V. et al. Neuroprotection by Hsp104 and Hsp27 in lentiviral-based rat models of Huntington’s disease. Mol Ther 15, 903–911, 
doi: 6300141 (2007).
53. Dandoy-Dron, F. et al. Infection by ME7 prion is not modified in transgenic mice expressing the yeast chaperone Hsp104 in 
neurons. Neurosci Lett 405, 181–185, doi: S0304-3940(06)00553-2 (2006).
54. Vacher, C., Garcia-Oroz, L. & Rubinsztein, D. C. Overexpression of yeast hsp104 reduces polyglutamine aggregation and prolongs 
survival of a transgenic mouse model of Huntington’s disease. Hum Mol Genet 14, 3425–3433, doi: ddi372 (2005).
55. Lo Bianco, C. et al. Hsp104 antagonizes alpha-synuclein aggregation and reduces dopaminergic degeneration in a rat model of 
Parkinson disease. J Clin Invest 118, 3087–3097, doi: 10.1172/JCI35781 (2008).
56. Baudin-Baillieu, A. et al. Genome-wide Translational Changes Induced by the Prion [PSI(+ )]. Cell Rep 8, 439–448, doi: 10.1016/j.
celrep.2014.06.036 (2014).
57. Wickner, R. B., Edskes, H. K., Bateman, D., Kelly, A. C. & Gorkovskiy, A. The yeast prions [PSI+ ] and [URE3] are molecular 
degenerative diseases. Prion 5, 258–262, doi: 10.4161/pri.17748 (2011).
58. Brundin, P., Melki, R. & Kopito, R. Prion-like transmission of protein aggregates in neurodegenerative diseases. Nat Rev Mol Cell 
Biol 11, 301–307, doi: 10.1038/nrm2873 nrm2873 (2010).
59. Frost, B. & Diamond, M. I. Prion-like mechanisms in neurodegenerative diseases. Nat Rev Neurosci 11, 155–159, doi: 10.1038/
nrn2786 (2010).
60. Bach, S. et al. A yeast-based assay to isolate drugs active against mammalian prions. Methods 39, 72–77 (2006).
61. Chernoff, Y. O., Lindquist, S. L., Ono, B., Inge-Vechtomov, S. G. & Liebman, S. W. Role of the chaperone protein Hsp104 in 
propagation of the yeast prion-like factor [psi+ ]. Science 268, 880–884 (1995).
62. Tanaka, M., Chien, P., Naber, N., Cooke, R. & Weissman, J. S. Conformational variations in an infectious protein determine prion 
strain differences. Nature 428, 323–328, doi: 10.1038/nature02392 (2004).
63. Guthrie, C. & Fink, G. R. In Methods in Enzymology Vol. 351, part C (ed academic press) (San Diego, California, 1991).
64. Longtine, M. S. et al. Additional modules for versatile and economical PCR-based gene deletion and modification in Saccharomyces 
cerevisiae. Yeast 14, 953–961, doi: 10.1002/(SICI)1097-0061(199807)14:10< 953::AID-YEA293> 3.0.CO;2-U (1998).
65. Wegierski, T., Billy, E., Nasr, F. & Filipowicz, W. Bms1p, a G-domain-containing protein, associates with Rcl1p and is required for 
18S rRNA biogenesis in yeast. RNA 7, 1254–1267 (2001).
66. Gelperin, D. M. et al. Biochemical and genetic analysis of the yeast proteome with a movable ORF collection. Genes Dev 19, 
2816–2826, doi: 19/23/2816 (2005).
www.nature.com/scientificreports/
1 4Scientific RepoRts | 6:32117 | DOI: 10.1038/srep32117
67. Escher, A., O’Kane, D. J., Lee, J. & Szalay, A. A. Bacterial luciferase alpha beta fusion protein is fully active as a monomer and highly 
sensitive in vivo to elevated temperature. Proceedings of the National Academy of Sciences of the United States of America 86, 
6528–6532 (1989).
68. Sanchez, Y., Taulien, J., Borkovich, K. A. & Lindquist, S. Hsp104 is required for tolerance to many forms of stress. EMBO J 11, 
2357–2364 (1992).
69. Hasin, N., Cusack, S. A., Ali, S. S., Fitzpatrick, D. A. & Jones, G. W. Global transcript and phenotypic analysis of yeast cells expressing 
Ssa1, Ssa2, Ssa3 or Ssa4 as sole source of cytosolic Hsp70-Ssa chaperone activity. BMC Genomics 15, 194, doi: 10.1186/1471-2164-
15-194 (2014).
70. Parsell, D. A., Kowal, A. S. & Lindquist, S. Saccharomyces cerevisiae Hsp104 protein. Purification and characterization of ATP-
induced structural changes. J Biol Chem 269, 4480–4487 (1994).
71. Parsell, D. A., Kowal, A. S., Singer, M. A. & Lindquist, S. Protein disaggregation mediated by heat-shock protein Hsp104. Nature 372, 
475–478, doi: 10.1038/372475a0 (1994).
72. Seiser, R. M. et al. Ltv1 is required for efficient nuclear export of the ribosomal small subunit in Saccharomyces cerevisiae. Genetics 
174, 679–691, doi: genetics.106.062117 (2006).
73. Patino, M. M., Liu, J. J., Glover, J. R. & Lindquist, S. Support for the prion hypothesis for inheritance of a phenotypic trait in yeast. 
Science 273, 622–626 (1996).
74. Pezza, J. A., Villali, J., Sindi, S. S. & Serio, T. R. Amyloid-associated activity contributes to the severity and toxicity of a prion 
phenotype. Nat Commun 5, 4384, doi: 10.1038/ncomms5384 (2014).
75. Chernoff, Y. O., Uptain, S. M. & Lindquist, S. L. Analysis of prion factors in yeast. Methods Enzymol 351, 499–538 (2002).
76. Tuite, M. F., Mundy, C. R. & Cox, B. S. Agents that cause a high frequency of genetic change from [psi+ ] to [psi− ] in Saccharomyces 
cerevisiae. Genetics 98, 691–711 (1981).
77. Derkatch, I. L. et al. Dependence and independence of [PSI(+ )] and [PIN(+ )]: a two-prion system in yeast? EMBO J 19, 1942–1952, 
doi: 10.1093/emboj/19.9.1942 (2000).
78. Samanta, D. et al. Protein folding by domain V of Escherichia coli 23S rRNA: specificity of RNA-protein interactions. J Bacteriol 190, 
3344–3352, doi: 10.1128/JB.01800-07 (2008).
79. Pang, Y. et al. The antiprion compound 6-Aminophenanthridine inhibits protein folding activity of the ribosome by direct 
competition. J Biol Chem, doi: M113.466748 (2013).
80. Kiss-Laszlo, Z., Henry, Y., Bachellerie, J. P., Caizergues-Ferrer, M. & Kiss, T. Site-specific ribose methylation of preribosomal RNA: 
a novel function for small nucleolar RNAs. Cell 85, 1077–1088, doi: S0092-8674(00)81308-2 (1996).
81. Kiss, T. Small nucleolar RNAs: an abundant group of noncoding RNAs with diverse cellular functions. Cell 109, 145–148, doi: 
S0092867402007183 (2002).
Acknowledgements
We thank L. Maillet, B. Abiven, S. Sanyal and S. Saupe for critical reading of the manuscript, and H. Simon 
for excellent technical assistance. We also thank S. Hermann and M. Fournier for the gift of plasmids allowing 
the creation of custom snoRNAs according to M. Fournier’s method and for advice in setting up the system; J. 
Delesques for help in preparing polysome profiles; K. Trillet for Q-PCR advice; and O. Billant and M.J. Lista 
for plate shaking support. We thank S. Liebman for the gift of RNQ1::GFP plasmid, J. Glover for anti-Hsp104 
antibodies and G. Rabut for BMS1-expressing plasmid.
Author Contributions
Conceptualization, M.B. and C.V.; Methodology, M.B., R.G., G.S., G.W.J. and C.V.; Investigation, F.S., J.E., P.N., 
N.H., S.C., M.-A.C. and C.V.; Writing –Original Draft, C.V.; Writing –Review and Editing, M.B., S.C., R.G., G.F., 
G.S., G.W.J. and C.V.; Visualization, C.V.; Funding Acquisition, M.B. and C.V.; Supervision, M.B. and C.V.
Additional Information
Supplementary information accompanies this paper at http://www.nature.com/srep
Competing financial interests: The authors declare no competing financial interests.
How to cite this article: Blondel, M. et al. Protein Folding Activity of the Ribosome is involved in Yeast Prion 
Propagation. Sci. Rep. 6, 32117; doi: 10.1038/srep32117 (2016).
This work is licensed under a Creative Commons Attribution 4.0 International License. The images 
or other third party material in this article are included in the article’s Creative Commons license, 
unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, 
users will need to obtain permission from the license holder to reproduce the material. To view a copy of this 
license, visit http://creativecommons.org/licenses/by/4.0/
 
© The Author(s) 2016
